Endocrinology

Back to articles

Vasopeptidase Inhibitors: Roles in Hypertension and Heart Failure

KEY POINT

An exciting new class of medications for treatment of hypertension and chronic heart failure could soon reach the U.S. market. The vasopeptidase inhibitors, by blocking the actions of angiotensin-converting enzyme (ACE) and neutral endopeptidase, have dual effects on the body’s complex system for regulating sodium and fluid homeostasis.

SOURCES

Nathisuwan S, Talbert RL. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure. Pharmacotherapy. 2002;22:27–42.

Rouleau JL et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615–20.

Coats AJS. Omapatrilat—the ups and downs of an exciting but complicated new drug [editorial]. Int J Cardiol. 2000;74:1–3.

Weber M. Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE). Presented at: American College of Cardiology Annual Scientific Session; March 20, 2002; Atlanta, Ga.

Packer M. Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Presented at: American College of Cardiology Annual Scientific Session; March 20, 2002; Atlanta, Ga.